2
Safe Harbor Statement
This communication contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on managements current
beliefs and expectations and involve a number of assumptions, known and unknown risks and uncertainties that change
over time and could cause future results, performance or achievements to differ materially
from the results, performance or achievements expressed or implied by such
forward-looking statements. These assumptions, known and unknown risks and uncertainties include, but are not limited to, those
discussed in our Annual Report on Form 20-F for the year ended December 31, 2014 and in
our other filings with the U.S. Securities and Exchange Commission (the
SEC), and those relating to Mylans business, as detailed from time to time in Mylans filings with the SEC, which factors are
incorporated herein by reference. Forward-looking statements are generally
identified by the words expects, anticipates, believes, intends,
estimates, will, would, could,
should, may, plans and similar expressions. All statements, other than statements of historical fact, are
statements that could be deemed to be forward-looking statements, including statements
about the proposed acquisition of Mylan, the financing of the proposed transaction, the
expected future performance (including expected results of operations and financial guidance), and the combined
companys future financial condition, operating results, strategy and plans.
Important factors that could cause actual results, performance or achievements to
differ materially from the forward-looking statements we make in this communication include, but are not limited to: the ultimate
outcome of any possible transaction between Teva and Mylan, including the possibility that no
transaction between Teva and Mylan will be effected or that a transaction will be
pursued on different terms and conditions; the effects of the business combination of Teva and Mylan, including the
combined companys future financial condition, operating results, strategy and plans;
uncertainties as to the timing of the transaction; the possibility that the expected
benefits of the transaction and the integration of our operations with Mylans operations (including any expected synergies) will not
be fully realized by us or may take longer to realize than expected; adverse effects on the
market price of Tevas or Mylans shares, including negative effects of this
communication or the consummation of the possible transaction; the ability to obtain regulatory approvals on the terms proposed or
expected and satisfy other conditions to the offer, including any necessary stockholder
approval, in each case, on a timely basis; our and Mylans ability to comply with
all covenants in our or its current or future indentures and credit facilities, any violation of which, if not cured in a timely manner, could
trigger a default of other obligations under cross default provisions; our and Mylans
exposure to currency fluctuations and restrictions as well as credit risks; the effects
of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; uncertainties surrounding the legislative and
regulatory pathways for the registration and approval of biotechnology-based medicines;
the impact of competition from other market participants; adverse effects of political
or economic instability, corruption, major hostilities or acts of terrorism on our or Mylans significant worldwide operations;
other risks, uncertainties and other factors detailed in our Annual Report on Form 20-F
for the year ended December 31, 2014 and in our other filings with the SEC; and the
risks and uncertainties and other factors detailed in Mylans reports and documents filed with the SEC. All forward-looking
statements attributable to us or any person acting on our behalf are expressly qualified in
their entirety by this cautionary statement. Readers are cautioned not to place undue
reliance on any of these forward-looking statements. Forward-looking statements speak only as of the date on which
they are made and we assume no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise.
|